Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EBIT (2016 - 2026)

Anika Therapeutics has reported EBIT over the past 17 years, most recently at -$5.5 million for Q1 2026.

  • Quarterly EBIT fell 28.1% to -$5.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$12.3 million through Mar 2026, down 78.12% year-over-year, with the annual reading at -$11.1 million for FY2025, 116.64% down from the prior year.
  • EBIT was -$5.5 million for Q1 2026 at Anika Therapeutics, down from $646000.0 in the prior quarter.
  • Over five years, EBIT peaked at $24.7 million in Q4 2023 and troughed at -$12.6 million in Q1 2023.
  • The 5-year median for EBIT is -$3.4 million (2022), against an average of -$1.0 million.
  • Year-over-year, EBIT soared 279.8% in 2022 and then crashed 3891.36% in 2025.
  • A 5-year view of EBIT shows it stood at $16.4 million in 2022, then skyrocketed by 50.59% to $24.7 million in 2023, then tumbled by 102.85% to -$705000.0 in 2024, then skyrocketed by 191.63% to $646000.0 in 2025, then tumbled by 949.54% to -$5.5 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's EBIT are -$5.5 million (Q1 2026), $646000.0 (Q4 2025), and -$3.2 million (Q3 2025).